• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

Novavax

FDA signals careful approach in authorizing COVID-19 vaccines in young children

May 2, 2022 By Brian Buntz

FDA is planning a series of virtual meetings of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) throughout June. In the meetings, the advisory committee will discuss authorizing the COVID-19 vaccine from Novavax (Nasdaq:NVAX) and authorizing the use of the vaccines from Moderna (Nasdaq: MRNA) and Pfizer-BioNTech (NYSE:PFE; Nasdaq:BNTX) in children aged 6 months […]

Filed Under: Featured, Pharmaceutical Tagged With: BioNTech, COVID-19 vaccines, FDA, Moderna, Novavax, NVX‑CoV2373, Pfizer, Vaccines and Related Biological Products Advisory Committee, VRBPAC

Takeda wins approval to distribute Novavax’s COVID-19 vaccine in Japan

April 20, 2022 By Brian Buntz

Takeda (NYSE:TAK) has announced that it has won manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for Nuvaxovid, a novel COVID-19 vaccine. Nuvaxovid (NVX-CoV2373) was initially developed by Novavax (Nasdaq:NVAX). The approval covers the use of the vaccine as both a primary and booster immunization in adults at least […]

Filed Under: Featured, News Well, Pharmaceutical Tagged With: coronavirus, COVID-19, COVID-19 vaccine, Novavax, Nuvaxovid, NVX-CoV2373, Takeda

Fujifilm to expand vaccine production plant in England

December 2, 2021 By Sean Whooley

Fujifilm (TSE:4901) is spending big to double the size of its United Kingdom-based vaccine manufacturing facility. According to a news release, Fujifilm is spending about $532.8 million (£400 million) to expand its Teesside (north-east England) plant making the Novavax COVID-19 vaccine. The expansion includes facilities specializing in antibody treatments and viral gene therapies. Fujifilm said […]

Filed Under: Business/Financial News, Contract Manufacturing, Featured, News Well, Pharmaceutical Tagged With: coronavirus, COVID-19, Fujifilm, Novavax

Novavax stock surges after striking EU COVID-19 vaccine deal

August 4, 2021 By Brian Buntz

Novavax (NSDQ:NVAX) saw its stock jump more than 20% in afternoon trading after the European Commission agreed to purchase up to 200 million doses of its vaccine.  The Gaithersburg, Md.–based vaccine maker announced in March that its NVX-CoV2373 vaccine was 96.4% effective against the original SARS-CoV-2 strain in a U.K. trial. The efficacy in a later trial […]

Filed Under: Featured, Pharmaceutical Tagged With: AstraZeneca plc, BioNTech, coronavirus, COVID-19, COVID-19 vaccine, COVID-19 vaccine trial, COVID-19 vaccines, Moderna, Novavax, Novavax Inc., NVX-CoV2373, Pfizer

Novavax’s COVID-19 vaccine demonstrates 90% efficacy

June 14, 2021 By Sean Whooley

Novavax (NSDQ:NVAX) announced today that its COVID-19 vaccine demonstrated 90.4% efficacy in protecting against COVID-19. Gaithersburg, Md.–based Novavax’s recombinant nanoparticle protein-based COVID-19 vaccine demonstrated 100% protection against moderate and severe disease, with 90.4% efficacy overall as it met the primary endpoint in the Prevent-19 pivotal Phase 3 trial. Get the full story at our sister site, […]

Filed Under: Clinical Trials, Featured, Pharmaceutical Tagged With: coronavirus, COVID-19, Novavax

Novax could have one of the most-effective COVID-19 vaccines

March 12, 2021 By Brian Buntz

Novavax (Gaithersburg, Md.) may not be the best-known vaccine developer, but its COVID-19 vaccine offers performance in line with those from Moderna and Pfizer. Its vaccine was 96.4% effective at preventing COVID-19 caused by the original strain of the virus in a Phase 3 study. The Moderna and Pfizer vaccines offered efficacy in the mid-90% […]

Filed Under: Pharmaceutical Tagged With: BioNTech, Clinical Trials, coronavirus, COVID-19, Moderna, Novavax, Novavax Inc., Pfizer

BREAKING: J&J’s Phase 3 COVID-19 vaccine study results raise more alarms about new variants

January 29, 2021 By Sean Whooley

Johnson & Johnson (NYSE:JNJ) announced results from its COVID-19 vaccine trial that show decreased effectiveness against new virus variants. The vaccine candidate from Johnson & Johnson’s Janssen Pharmaceutical Companies was 66% effective overall in preventing moderate to severe COVID-19 28 days after vaccination. But it proved less effective in South Africa, where a new variant of […]

Filed Under: Clinical Trials, Featured, Pharmaceutical Tagged With: coronavirus, COVID-19, COVID-19 vaccine, COVID-19 vaccine trial, Janssen Pharmaceuticals, Johnson & Johnson, Moderna, Novavax

Novavax launches Phase 3 COVID-19 vaccine trial in UK

September 24, 2020 By Nancy Crotti

Novavax (NSDQ:NVAX) today announced that it has begun its first Phase 3 study to evaluate the efficacy, safety and immunogenicity of its COVID-19 vaccine candidate, NVX-CoV2373. The trial is underway in the UK, in partnership with the UK government’s Vaccines Taskforce. Gaithersburg, Md.-based Novavax said it expects to enroll up to 10,000 individuals between 18 and […]

Filed Under: Business/Financial News, Clinical Trials, Featured, Pharmaceutical Tagged With: coronavirus, COVID-19, Novavax

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy